Speakers
Adam Byrne
Professor
Imperial College London
Day 2
Wednesday March 9, 2022
2:30 pm | The Role of Macrophage Metabolic Reprogramming During Pulmonary Fibrosis
Cara Williams
Vice President & Head of Preclinical Biology: Inflammation & Immunology Research Unit
Pfizer
Day 1
Tuesday March 8, 2022
9:00 am | Comparing & Contrasting Fibrotic & Inflammatory ILDs in Order to Comprehensively Understand Key Differences in Their Development & Progression & Learning How This Influences Drug Development
Carsten Ehrhardt
Professor of Pharmacy
Trinity College Dublin
Pre-Conference Day
Monday, March 7, 2022
11:00 am | Integrating Inhaled Therapeutics with ILD Mechanisms to Streamline Your Drug Delivery
10:30 am | Considerations for Inhaled Drug Delivery
Track A, AM
Monday, March 7
2:00 pm | Moderated Discussion: Analyzing Biologics, Small Molecules & Antibodies for the Treatment of ILD to Determine Which One is Most Easily Inhaled, Nebulized & Absorbed by the Alveoli
Track A, PM
Monday, March 7
3:30 pm | Advantages & Disadvantages of Different Molecule Types for Inhaled Drug Delivery
Craig Conoscenti
Medical Expert ILD Respiratory Clinical Development & Medical Affairs
Boehringer Ingelheim
Day 2
Wednesday March 9, 2022
9:00 am | Strategically Leveraging ILD Clinical Trials to Further Our Understanding of The Progressive Pulmonary Fibrosis Phenotype & Identify Novel Outcomes in Clinical Trials
David Barber
Professor of Machine Learning
UCL
Day 1
Tuesday March 8, 2022
11:30 am | OSIC Project – Exploring Imaging Based Biomarkers, CT Scans/ Data Collection to Predict FVC Decline
Dinesh Khanna
Professor
University of Michigan
Day 1
Tuesday March 8, 2022
10:00 am | Designing Trials for Inflammatory ILDs in 2022 & Beyond: Spotlight on Ssc-ILD
Elizabeth Renzoni
Consultant Respiratory Physician, Honorary Senior Lecturer
Imperial College London
Day 1
Tuesday March 8, 2022
2:00 pm | Exploring Endpoints in the Context of Inflammatory ILDs: Debating Which Factors You Must Measure to Accurately Assess the Efficacy of Treatment in Inflammatory vs Fibrotic ILDs
Eric White
Senior Clinical Program Lead
Boehringer Ingelheim
Day 2
Wednesday March 9, 2022
9:30 am | Looking Beyond IPF: Utilizing Lessons Learned from IPF Clinical Trials to Inform & Optimize Your ILD Trial Design & Execution
Farrell Simon
Vice President & Head of US Marketing
Trevi Therapeutics
Day 1
Tuesday March 8, 2022
1:00 pm | Exploring the Impact & Importance of Quality of Life on the Patient Journey
Glenn Rosen
Chief Scientific Officer
Optikira & Biomotiv
Day 2
Wednesday March 9, 2022
4:30 pm | Revealing What Steps You Must Take to Successfully Identify & Validate Novel ILD Therapeutic Targets which Target Lung Epithelial injury
Jason Laufer
Chief Executive Officer
Remedy Cell
Track A, AM
Monday, March 7
2:30 pm | Harnessing the Therapeutic Power of Secretomes to Treat IPF & the Challenges of Optimizing Inhaled Drug Delivery
Track A, PM
Monday, March 7
3:30 pm | Advantages & Disadvantages of Different Molecule Types for Inhaled Drug Delivery
Majd Mouded
Executive Director for BioMedical Research
Novartis
Day 2
Wednesday March 9, 2022
10:00 am | Uncovering Trial Design Considerations in Sarcoid
Margaret Neighbors
Principle Scientist
Genentech
Track B, AM
Monday, March 7
2:30 pm | Considerations for Clinical Trial Biomarker Selection
2:00 pm | Learning how to Use Biomarkers to Distinguish Patients with Fibrotic vs Inflammatory ILD in Order to Strategically Stratify Trial Populations & Maximize Trial Efficiency
Martin Kolb
Professor
McMaster University
Day 1
Tuesday March 8, 2022
4:00 pm | Scrutinizing the Practicalities of Deciding When to Lump or Split in the Context of Disease Progression in Order to Inform & Optimize Your ILD Drug Development Strategy
Matt Bradley
Founder, Chairman, President, & Chief Technical Officer
SAJE Pharma
Day 2
Wednesday March 9, 2022
1:00 pm | Single vs Multiple Benefit Drugs for ILD
Nicolas Guisot
Research Fellow & Project Leader
Redx Pharma
Day 2
Wednesday March 9, 2022
4:00 pm | Selective Inhibition of ROCK2: Promising Approach to Target Fibrosis
Nina Patel
Director – Clinical Development & Medical Affairs ILD
Boehringer Ingelheim
Day 1
Tuesday March 8, 2022
9:30 am | Understanding How to Define Patient Populations, Select Optimal Intervention Points & Outline Clear Therapeutic Outcomes to Streamline the Design & Development of Therapies for Inflammatory ILDs
Paolo Cameli
Pulmonologist
University of Siena
Day 1
Tuesday March 8, 2022
12:00 pm | Exploring Biomarkers for Differential Diagnosis of Interstitial Lung Diseases
Peter Fernandes
Vice President & Chief Regulatory, Quality & Safety Officer
Bellerophon Therapeutics
Day 1
Tuesday March 8, 2022
1:30 pm | Devising & Developing Composite Endpoints Which are Realistic & Achievable to Use in Your Next Clinical Trial
Pre-Conference Day
Monday, March 7, 2022
11:00 am | Integrating Inhaled Therapeutics with ILD Mechanisms to Streamline Your Drug Delivery
10:00 am | Deep Diving into Delivery Mechanisms: Comparing & Contrasting Inhaled vs Systemic Drug Delivery in the Context of ILD Treatment
Rohit Batta
Chief Scientific Officer
Vicore Pharma
Day 2
Wednesday March 9, 2022
11:30 am | Developing Therapies for Rare Lung Diseases: ILD 101
Shane Olwill
Senior Vice President & Chief Development Officer
Pieris Pharmaceuticals
Track A, AM
Monday, March 7
2:00 pm | Moderated Discussion: Analyzing Biologics, Small Molecules & Antibodies for the Treatment of ILD to Determine Which One is Most Easily Inhaled, Nebulized & Absorbed by the Alveoli
Track A, PM
Monday, March 7
3:30 pm | Advantages & Disadvantages of Different Molecule Types for Inhaled Drug Delivery
Shannon Turley
Vice President of Cancer Immunology Discovery
Genentech
Day 2
Wednesday March 9, 2022
2:00 pm | Evolution of Multicellular Hubs in the Tumor Microenvironment & their Relevance for ILD Drug Development
Shervin Assassi
Director of the Division of Rheumatology
The University of Texas
Track B, PM
Monday, March 7
4:00 pm | Enrichment Strategies on SSc-ILD Clinical Trials
Simon Walsh
Consultant Thoracic Radiologist, Machine Learning Scientist & Imaging Chair
Imperial College London
Day 1
Tuesday March 8, 2022
3:30 pm | Machine Learning & Interstitial Lung Disease: A Deep Dive
Steve Jones
President
EUIPFF
Pre-Conference Day
Monday, March 7, 2022
12:00 pm | Exploring the Patient Perspective on Inhaled Drug Delivery
Tejaswini Kulkarni
Director of Interstitial Lung Disease Program
University of Alabama
Track B, AM
Monday, March 7
2:30 pm | Considerations for Clinical Trial Biomarker Selection
1:30 pm | Utilizing Biomarkers to Identify Patient Populations Which are More Receptive to Your ILD Therapeutic in Order to Design and Conduct Faster Trials in a Shorter Time Frame
Toby Maher
Director, Interstitial Lung Disease Program
USC
Track A, PM
Monday, March 7
4:00 pm | Practical Experience of Delivering Inhaled Drugs in Fibrotic Lung Disease
Vanessa Neins
Senior Scientist - Biology Lead Respiratory
Pieris Pharmaceuticals
Day 2
Wednesday March 9, 2022